Spots Global Cancer Trial Database for Prospective Validation of the OHI Index

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Prospective Validation of the OHI Index

Official Title: A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index

Study ID: NCT05882175

Conditions

HLH

Hemophagocytic Lymphohistiocytoses

Hemophagocytic Syndrome

Hematologic Malignancy

Hematologic Neoplasms

Interventions

Study Description

Brief Summary: Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). We have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \> 3,900 U/mL and ferritin \>1,000 ng/mL . However, the true incidence and outcomes of HLH/OHI+ in an unselected cohort are unknown and so is the mechanism of HM-HLH.

Detailed Description: The investigators will enroll patients with new/transformed hematologic malignancies. We will follow the patients until the end of the study, report their survival at one year and examine their prognosis.